# Aspen Aerogels Inc: financial statements, quarterly

ASPN · NYSE · CIK 1145986 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aspn.md) · [Financials](/companies/aspn/financials.md) · [Filings](/companies/aspn/filings.md) · [Insiders](/companies/aspn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aspn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [60.8](/filings/0000950170-24-123427.md) | [84.2 d](/filings/0001193125-26-119892.md) | [94.5](/filings/0000950170-25-066992.md) | [118](/filings/0001193125-25-175489.md) | [117](/filings/0001193125-25-270038.md) | [123 d](/filings/0001193125-26-119892.md) | [78.7](/filings/0001193125-26-214672.md) | [78.0](/filings/0001193125-26-340275.md) | [73.0](/filings/0001193125-25-270038.md) | [41.3 d](/filings/0001193125-26-119892.md) | [37.9](/filings/0001193125-26-214672.md) | [49.8](/filings/0001193125-26-340275.md) |
| Cost of revenue | $m | [46.9](/filings/0000950170-24-123427.md) | [54.6 d](/filings/0001193125-26-119892.md) | [59.4](/filings/0000950170-25-066992.md) | [66.2](/filings/0001193125-25-175489.md) | [68.3](/filings/0001193125-25-270038.md) | [76.0 d](/filings/0001193125-26-119892.md) | [55.9](/filings/0001193125-26-214672.md) | [52.7](/filings/0001193125-26-340275.md) | [52.2](/filings/0001193125-25-270038.md) | [64.3 d](/filings/0001193125-26-119892.md) | [33.6](/filings/0001193125-26-214672.md) | [46.6](/filings/0001193125-26-340275.md) |
| Gross profit | $m | [13.8](/filings/0000950170-24-123427.md) | [29.6 d](/filings/0001193125-26-119892.md) | [35.1](/filings/0000950170-25-066992.md) | [51.6](/filings/0001193125-25-175489.md) | [49.0](/filings/0001193125-25-270038.md) | [47.1 d](/filings/0001193125-26-119892.md) | [22.8](/filings/0001193125-26-214672.md) | [25.3](/filings/0001193125-26-340275.md) | [20.8](/filings/0001193125-25-270038.md) | [(22.9) d](/filings/0001193125-26-119892.md) | [4.3](/filings/0001193125-26-214672.md) | [3.3](/filings/0001193125-26-340275.md) |
| Research and development | $m | [4.2](/filings/0000950170-24-123427.md) | [4.1 d](/filings/0001193125-26-119892.md) | [4.5](/filings/0000950170-25-066992.md) | [4.6](/filings/0001193125-25-175489.md) | [4.6](/filings/0001193125-25-270038.md) | [4.4 d](/filings/0001193125-26-119892.md) | [4.3](/filings/0001193125-26-214672.md) | [3.8](/filings/0001193125-26-340275.md) | [2.5](/filings/0001193125-25-270038.md) | [2.8 d](/filings/0001193125-26-119892.md) | [2.7](/filings/0001193125-26-214672.md) | [3.2](/filings/0001193125-26-340275.md) |
| Operating income | $m | [(14.6)](/filings/0000950170-24-123427.md) | [1.4 d](/filings/0001193125-26-119892.md) | [2.4](/filings/0000950170-25-066992.md) | [20.0](/filings/0001193125-25-175489.md) | [17.4](/filings/0001193125-25-270038.md) | [14.7 d](/filings/0001193125-26-119892.md) | [(299)](/filings/0001193125-26-214672.md) | [(5.2)](/filings/0001193125-26-340275.md) | [(3.3)](/filings/0001193125-25-270038.md) | [(70.4) d](/filings/0001193125-26-119892.md) | [(20.8)](/filings/0001193125-26-214672.md) | [(28.8)](/filings/0001193125-26-340275.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | [0.8](/filings/0000950170-25-066992.md) | [0.9](/filings/0001193125-25-175489.md) | [0.3](/filings/0001193125-25-270038.md) | [(0.2) d](/filings/0001193125-26-119892.md) | [1.1](/filings/0001193125-26-214672.md) | [0.8](/filings/0001193125-26-340275.md) | [0.6](/filings/0001193125-25-270038.md) | [(0.1) d](/filings/0001193125-26-119892.md) | [(0.3)](/filings/0001193125-26-214672.md) | [0.6](/filings/0001193125-26-340275.md) |
| Net income | $m | [(13.1)](/filings/0000950170-24-123427.md) | [(0.5) d](/filings/0001193125-26-119892.md) | [(1.8)](/filings/0001193125-25-270038.md) | [16.8](/filings/0001193125-25-270038.md) | [(13.0)](/filings/0001193125-25-270038.md) | [11.4 d](/filings/0001193125-26-119892.md) | [(301)](/filings/0001193125-26-340275.md) | [(9.1)](/filings/0001193125-26-340275.md) | [(6.3)](/filings/0001193125-25-270038.md) | [(72.9) d](/filings/0001193125-26-119892.md) | [(23.7)](/filings/0001193125-26-340275.md) | [(23.3)](/filings/0001193125-26-340275.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0000950170-24-123427.md) | not reported | [(0.02)](/filings/0000950170-25-066992.md) | [0.21](/filings/0001193125-25-175489.md) | [(0.17)](/filings/0001193125-25-270038.md) | not reported | [(3.67)](/filings/0001193125-26-214672.md) | [(0.11)](/filings/0001193125-26-340275.md) | [(0.08)](/filings/0001193125-25-270038.md) | not reported | [(0.29)](/filings/0001193125-26-214672.md) | [(0.28)](/filings/0001193125-26-340275.md) |
| Basic EPS | $ per share | [(0.19)](/filings/0000950170-24-123427.md) | not reported | [(0.02)](/filings/0000950170-25-066992.md) | [0.22](/filings/0001193125-25-175489.md) | [(0.17)](/filings/0001193125-25-270038.md) | not reported | [(3.67)](/filings/0001193125-26-214672.md) | [(0.11)](/filings/0001193125-26-340275.md) | [(0.08)](/filings/0001193125-25-270038.md) | not reported | [(0.29)](/filings/0001193125-26-214672.md) | [(0.28)](/filings/0001193125-26-340275.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [94.6](/filings/0000950170-23-058227.md) | [140](/filings/0000950170-25-029252.md) | [101](/filings/0000950170-24-052139.md) | [91.4](/filings/0000950170-24-094005.md) | [113](/filings/0000950170-24-123427.md) | [221](/filings/0001193125-26-119892.md) | [192](/filings/0000950170-25-066992.md) | [168](/filings/0001193125-25-175489.md) | [151](/filings/0001193125-25-270038.md) | [157](/filings/0001193125-26-340275.md) | [174](/filings/0001193125-26-214672.md) | [152](/filings/0001193125-26-340275.md) |
| Current assets | $m | [200](/filings/0000950170-23-058227.md) | [266](/filings/0000950170-25-029252.md) | [255](/filings/0000950170-24-052139.md) | [289](/filings/0000950170-24-094005.md) | [306](/filings/0000950170-24-123427.md) | [409](/filings/0001193125-26-119892.md) | [344](/filings/0000950170-25-066992.md) | [310](/filings/0001193125-25-175489.md) | [279](/filings/0001193125-25-270038.md) | [242](/filings/0001193125-26-340275.md) | [254](/filings/0001193125-26-214672.md) | [248](/filings/0001193125-26-340275.md) |
| Total assets | $m | [605](/filings/0000950170-23-058227.md) | [703](/filings/0000950170-25-029252.md) | [698](/filings/0000950170-24-052139.md) | [749](/filings/0000950170-24-094005.md) | [783](/filings/0000950170-24-123427.md) | [895](/filings/0001193125-26-119892.md) | [555](/filings/0000950170-25-066992.md) | [525](/filings/0001193125-25-175489.md) | [491](/filings/0001193125-25-270038.md) | [407](/filings/0001193125-26-340275.md) | [410](/filings/0001193125-26-214672.md) | [393](/filings/0001193125-26-340275.md) |
| Current liabilities | $m | [61.3](/filings/0000950170-23-058227.md) | [78.1](/filings/0000950170-25-029252.md) | [63.6](/filings/0000950170-24-052139.md) | [83.4](/filings/0000950170-24-094005.md) | [104](/filings/0000950170-24-123427.md) | [110](/filings/0001193125-26-119892.md) | [81.4](/filings/0000950170-25-066992.md) | [78.0](/filings/0001193125-25-175489.md) | [70.7](/filings/0001193125-25-270038.md) | [62.0](/filings/0001193125-26-340275.md) | [87.8](/filings/0001193125-26-214672.md) | [98.6](/filings/0001193125-26-340275.md) |
| Total liabilities | $m | [195](/filings/0000950170-23-058227.md) | [215](/filings/0000950170-25-029252.md) | [207](/filings/0000950170-24-052139.md) | [231](/filings/0000950170-24-094005.md) | [275](/filings/0000950170-24-123427.md) | [280](/filings/0001193125-26-119892.md) | [240](/filings/0000950170-25-066992.md) | [216](/filings/0001193125-25-175489.md) | [186](/filings/0001193125-25-270038.md) | [171](/filings/0001193125-26-340275.md) | [197](/filings/0001193125-26-214672.md) | [200](/filings/0001193125-26-340275.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | [93.7](/filings/0000950170-24-123427.md) | [95.0](/filings/0001193125-26-119892.md) | [95.4](/filings/0000950170-25-066992.md) | [77.3](/filings/0001193125-25-175489.md) | [70.1](/filings/0001193125-25-270038.md) | [65.5](/filings/0001193125-26-340275.md) | [61.2](/filings/0001193125-26-214672.md) | [57.0](/filings/0001193125-26-340275.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | [26.3](/filings/0000950170-24-123427.md) | [19.8](/filings/0001193125-26-119892.md) | [13.5](/filings/0000950170-25-066992.md) | [26.0](/filings/0001193125-25-175489.md) | [26.0](/filings/0001193125-25-270038.md) | [25.1](/filings/0001193125-26-340275.md) | [24.2](/filings/0001193125-26-214672.md) | [23.3](/filings/0001193125-26-340275.md) |
| Shareholders' equity | $m | [410](/filings/0000950170-24-123427.md) | [488](/filings/0001193125-26-119892.md) | [491](/filings/0001193125-25-270038.md) | [518](/filings/0001193125-25-270038.md) | [508](/filings/0001193125-25-270038.md) | [615](/filings/0001193125-26-340275.md) | [315](/filings/0001193125-26-340275.md) | [309](/filings/0001193125-26-340275.md) | [306](/filings/0001193125-25-270038.md) | [236](/filings/0001193125-26-340275.md) | [213](/filings/0001193125-26-340275.md) | [192](/filings/0001193125-26-340275.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.5) d](/filings/0000950170-24-123427.md) | [(2.8) d](/filings/0001193125-26-119892.md) | [(17.7)](/filings/0000950170-25-066992.md) | [6.8 d](/filings/0001193125-25-175489.md) | [20.8 d](/filings/0001193125-25-270038.md) | [35.7 d](/filings/0001193125-26-119892.md) | [5.6](/filings/0001193125-26-214672.md) | [(3.9) d](/filings/0001193125-26-340275.md) | [15.0 d](/filings/0001193125-25-270038.md) | [16.1 d](/filings/0001193125-26-119892.md) | [34.1](/filings/0001193125-26-214672.md) | [(16.2) d](/filings/0001193125-26-340275.md) |
| Capital expenditure | $m | [32.3 d](/filings/0000950170-24-123427.md) | [27.8 d](/filings/0001193125-26-119892.md) | [25.9](/filings/0000950170-25-066992.md) | [24.8 d](/filings/0001193125-25-175489.md) | [20.8 d](/filings/0001193125-25-270038.md) | [14.8 d](/filings/0001193125-26-119892.md) | [13.0](/filings/0001193125-26-214672.md) | [12.9 d](/filings/0001193125-26-340275.md) | [9.1 d](/filings/0001193125-25-270038.md) | [2.5 d](/filings/0001193125-26-119892.md) | [1.4](/filings/0001193125-26-214672.md) | [1.8 d](/filings/0001193125-26-340275.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.5](/filings/0000950170-23-058227.md) | [69.2](/filings/0000950170-24-052139.md) | [69.2](/filings/0000950170-24-094005.md) | [69.3](/filings/0000950170-24-123427.md) | [75.8](/filings/0000950170-25-066992.md) | [79.0](/filings/0001193125-25-175489.md) | [76.3](/filings/0001193125-25-270038.md) | [82.1](/filings/0001193125-26-214672.md) | [82.2](/filings/0001193125-26-340275.md) | [82.4](/filings/0001193125-25-270038.md) | [82.7](/filings/0001193125-26-214672.md) | [82.9](/filings/0001193125-26-340275.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 82,988,784 at 2026-08-04, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340275.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.